Cargando…
Cognitive disorder and dementia in type 2 diabetes mellitus
Insulin, a key pleiotropic hormone, regulates metabolism through several signaling pathways in target tissues including skeletal muscle, liver, and brain. In the brain, insulin modulates learning and memory, and impaired insulin signaling is associated with metabolic dysregulation and neurodegenerat...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052006/ https://www.ncbi.nlm.nih.gov/pubmed/35582669 http://dx.doi.org/10.4239/wjd.v13.i4.319 |
_version_ | 1784696691032588288 |
---|---|
author | Ortiz, Genaro G Huerta, Miguel González-Usigli, Héctor A Torres-Sánchez, Erandis D Delgado-Lara, Daniela LC Pacheco-Moisés, Fermín P Mireles-Ramírez, Mario A Torres-Mendoza, Blanca MG Moreno-Cih, Roxana I Velázquez-Brizuela, Irma E |
author_facet | Ortiz, Genaro G Huerta, Miguel González-Usigli, Héctor A Torres-Sánchez, Erandis D Delgado-Lara, Daniela LC Pacheco-Moisés, Fermín P Mireles-Ramírez, Mario A Torres-Mendoza, Blanca MG Moreno-Cih, Roxana I Velázquez-Brizuela, Irma E |
author_sort | Ortiz, Genaro G |
collection | PubMed |
description | Insulin, a key pleiotropic hormone, regulates metabolism through several signaling pathways in target tissues including skeletal muscle, liver, and brain. In the brain, insulin modulates learning and memory, and impaired insulin signaling is associated with metabolic dysregulation and neurodegenerative diseases. At the receptor level, in aging and Alzheimer’s disease (AD) models, the amount of insulin receptors and their functions are decreased. Clinical and animal model studies suggest that memory improvements are due to changes in insulin levels. Furthermore, diabetes mellitus (DM) and insulin resistance are associated with age-related cognitive decline, increased levels of β-amyloid peptide, phosphorylation of tau protein; oxidative stress, pro-inflammatory cytokine production, and dyslipidemia. Recent evidence shows that deleting brain insulin receptors leads to mild obesity and insulin resistance without influencing brain size and apoptosis development. Conversely, deleting insulin-like growth factor 1 receptor (IGF-1R) affects brain size and development, and contributes to behavior changes. Insulin is synthesized locally in the brain and is released from the neurons. Here, we reviewed proposed pathophysiological hypotheses to explain increased risk of dementia in the presence of DM. Regardless of the exact sequence of events leading to neurodegeneration, there is strong evidence that mitochondrial dysfunction plays a key role in AD and DM. A triple transgenic mouse model of AD showed mitochondrial dysfunction, oxidative stress, and loss of synaptic integrity. These alterations are comparable to those induced in wild-type mice treated with sucrose, which is consistent with the proposal that mitochondrial alterations are associated with DM and contribute to AD development. Alterations in insulin/IGF-1 signaling in DM could lead to mitochondrial dysfunction and low antioxidant capacity of the cell. Thus, insulin/IGF-1 signaling is important for increased neural processing and systemic metabolism, and could be a specific target for therapeutic strategies to decrease alterations associated with age-related cognitive decline. |
format | Online Article Text |
id | pubmed-9052006 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-90520062022-05-16 Cognitive disorder and dementia in type 2 diabetes mellitus Ortiz, Genaro G Huerta, Miguel González-Usigli, Héctor A Torres-Sánchez, Erandis D Delgado-Lara, Daniela LC Pacheco-Moisés, Fermín P Mireles-Ramírez, Mario A Torres-Mendoza, Blanca MG Moreno-Cih, Roxana I Velázquez-Brizuela, Irma E World J Diabetes Minireviews Insulin, a key pleiotropic hormone, regulates metabolism through several signaling pathways in target tissues including skeletal muscle, liver, and brain. In the brain, insulin modulates learning and memory, and impaired insulin signaling is associated with metabolic dysregulation and neurodegenerative diseases. At the receptor level, in aging and Alzheimer’s disease (AD) models, the amount of insulin receptors and their functions are decreased. Clinical and animal model studies suggest that memory improvements are due to changes in insulin levels. Furthermore, diabetes mellitus (DM) and insulin resistance are associated with age-related cognitive decline, increased levels of β-amyloid peptide, phosphorylation of tau protein; oxidative stress, pro-inflammatory cytokine production, and dyslipidemia. Recent evidence shows that deleting brain insulin receptors leads to mild obesity and insulin resistance without influencing brain size and apoptosis development. Conversely, deleting insulin-like growth factor 1 receptor (IGF-1R) affects brain size and development, and contributes to behavior changes. Insulin is synthesized locally in the brain and is released from the neurons. Here, we reviewed proposed pathophysiological hypotheses to explain increased risk of dementia in the presence of DM. Regardless of the exact sequence of events leading to neurodegeneration, there is strong evidence that mitochondrial dysfunction plays a key role in AD and DM. A triple transgenic mouse model of AD showed mitochondrial dysfunction, oxidative stress, and loss of synaptic integrity. These alterations are comparable to those induced in wild-type mice treated with sucrose, which is consistent with the proposal that mitochondrial alterations are associated with DM and contribute to AD development. Alterations in insulin/IGF-1 signaling in DM could lead to mitochondrial dysfunction and low antioxidant capacity of the cell. Thus, insulin/IGF-1 signaling is important for increased neural processing and systemic metabolism, and could be a specific target for therapeutic strategies to decrease alterations associated with age-related cognitive decline. Baishideng Publishing Group Inc 2022-04-15 2022-04-15 /pmc/articles/PMC9052006/ /pubmed/35582669 http://dx.doi.org/10.4239/wjd.v13.i4.319 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Minireviews Ortiz, Genaro G Huerta, Miguel González-Usigli, Héctor A Torres-Sánchez, Erandis D Delgado-Lara, Daniela LC Pacheco-Moisés, Fermín P Mireles-Ramírez, Mario A Torres-Mendoza, Blanca MG Moreno-Cih, Roxana I Velázquez-Brizuela, Irma E Cognitive disorder and dementia in type 2 diabetes mellitus |
title | Cognitive disorder and dementia in type 2 diabetes mellitus |
title_full | Cognitive disorder and dementia in type 2 diabetes mellitus |
title_fullStr | Cognitive disorder and dementia in type 2 diabetes mellitus |
title_full_unstemmed | Cognitive disorder and dementia in type 2 diabetes mellitus |
title_short | Cognitive disorder and dementia in type 2 diabetes mellitus |
title_sort | cognitive disorder and dementia in type 2 diabetes mellitus |
topic | Minireviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052006/ https://www.ncbi.nlm.nih.gov/pubmed/35582669 http://dx.doi.org/10.4239/wjd.v13.i4.319 |
work_keys_str_mv | AT ortizgenarog cognitivedisorderanddementiaintype2diabetesmellitus AT huertamiguel cognitivedisorderanddementiaintype2diabetesmellitus AT gonzalezusiglihectora cognitivedisorderanddementiaintype2diabetesmellitus AT torressanchezerandisd cognitivedisorderanddementiaintype2diabetesmellitus AT delgadolaradanielalc cognitivedisorderanddementiaintype2diabetesmellitus AT pachecomoisesferminp cognitivedisorderanddementiaintype2diabetesmellitus AT mirelesramirezmarioa cognitivedisorderanddementiaintype2diabetesmellitus AT torresmendozablancamg cognitivedisorderanddementiaintype2diabetesmellitus AT morenocihroxanai cognitivedisorderanddementiaintype2diabetesmellitus AT velazquezbrizuelairmae cognitivedisorderanddementiaintype2diabetesmellitus |